BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics.

IF 3 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pub Date : 2025-05-20 eCollection Date: 2025-01-01 DOI:10.2147/DMSO.S507699

Limin Zhai, Yue Wang, Li Xiang, Liang-Ping Ni, Deyuan Zhang, Tianrong Pan

{"title":"BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics.","authors":"Limin Zhai, Yue Wang, Li Xiang, Liang-Ping Ni, Deyuan Zhang, Tianrong Pan","doi":"10.2147/DMSO.S507699","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the effects of sacubitril/valsartan on diabetic nephropathy patients by blood-oxygenation-level dependent-magnetic resonance imaging (BOLD-MRI).Methods: Forty-eight Patients with diabetic kidney disease (DKD) admitted to our hospital from April 2023 to December 2024 were selected. They were divided into two groups based on the treatment obtained. The dapagliflozin group included dapagliflozin 10 mg once daily, and the Sacubitril/valsartan group included a combination of dapagliflozin and sacubitril/valsartan for 12 weeks. The plasma and urine biochemistry parameters of all patients were compared. Meanwhile, renal was scanned by BOLD MRI before and after experiment endpoint.Results: After 12 weeks treatment, biochemical indexes from baseline were improved in both dapagliflozin group and sacubitril/valsartan group. Sacubitril/valsartan treatment significantly reduced UACR and UNAG excretion, as well as decreased the R2* values of the kidney medulla, compared to the dapagliflozin group (p < 0.05).Conclusion: Sacubitril/valsartan can provide protection in DKD by reducing UACR and UNAG excretion while improving the oxygenation of the medulla area of the kidney, beyond its hypoglycemic and antihypertensive effects.","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"1661-1670"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DMSO.S507699","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the effects of sacubitril/valsartan on diabetic nephropathy patients by blood-oxygenation-level dependent-magnetic resonance imaging (BOLD-MRI).

Methods: Forty-eight Patients with diabetic kidney disease (DKD) admitted to our hospital from April 2023 to December 2024 were selected. They were divided into two groups based on the treatment obtained. The dapagliflozin group included dapagliflozin 10 mg once daily, and the Sacubitril/valsartan group included a combination of dapagliflozin and sacubitril/valsartan for 12 weeks. The plasma and urine biochemistry parameters of all patients were compared. Meanwhile, renal was scanned by BOLD MRI before and after experiment endpoint.

Results: After 12 weeks treatment, biochemical indexes from baseline were improved in both dapagliflozin group and sacubitril/valsartan group. Sacubitril/valsartan treatment significantly reduced UACR and UNAG excretion, as well as decreased the R2* values of the kidney medulla, compared to the dapagliflozin group (p < 0.05).

Conclusion: Sacubitril/valsartan can provide protection in DKD by reducing UACR and UNAG excretion while improving the oxygenation of the medulla area of the kidney, beyond its hypoglycemic and antihypertensive effects.

查看原文本刊更多论文

BOLD MRI评价苏比利/缬沙坦对2型糖尿病患者肾脏保护的作用。

目的：通过血氧水平依赖磁共振成像（BOLD-MRI）研究苏比里尔/缬沙坦对糖尿病肾病患者的影响。方法：选取2023年4月~ 2024年12月我院收治的糖尿病肾病（DKD）患者48例。根据治疗效果分为两组。达格列净组使用达格列净10mg，每日1次，萨奎比里尔/缬沙坦组使用达格列净和萨奎比里尔/缬沙坦联合使用，疗程12周。比较所有患者的血浆和尿液生化指标。同时，在实验终点前后对肾脏进行BOLD MRI扫描。结果：治疗12周后，达格列净组和苏比里尔/缬沙坦组的生化指标均较基线有所改善。与达格列净组相比，Sacubitril/缬沙坦治疗显著降低UACR和UNAG排泄，降低肾髓质R2*值（p < 0.05）。结论：沙比利/缬沙坦除具有降糖降压作用外，还可通过减少UACR和UNAG排泄，改善肾髓质区氧合，对DKD有保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.90

自引率

6.10%

发文量

431

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal. The journal is committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication.